Hastings Paul J
CIK 0001309702 Name as filed on the most recent filing
Filed as Hastings Paul J (41)
56 transaction lines · from 41 filings · filed 2005-04-29 to 2026-06-22 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Nkarta, Inc. 13 filings
- ISSUER Pacira BioSciences, Inc. 19 filings
- ISSUER OncoMed Pharmaceuticals Inc 6 filings
- ISSUER Relypsa Inc 2 filings
- ISSUER QLT Inc/BC 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
56 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-18 |
Nkarta, Inc. NKTX |
S, Open-market sale | 1,776 disposed | 2.71 | 4,812.96 | Form 4, filing 0001193125-26-277507 | |
| 2026-01-15 |
Nkarta, Inc. NKTX |
S, Open-market sale | 26,046 disposed | 2.07 | 53,915.22 | Form 4, filing 0001193125-26-016865 | |
| 2025-06-18 |
Nkarta, Inc. NKTX |
S, Open-market sale | 1,790 disposed | 1.79 | 3,204.10 | Form 4, filing 0000950170-25-088501 | |
| 2025-01-15 |
Nkarta, Inc. NKTX |
S, Open-market sale | 17,378 disposed | 2.20 | 38,231.60 | Form 4, filing 0000950170-25-006824 | |
| 2024-06-18 |
Nkarta, Inc. NKTX |
S, Open-market sale | 1,770 disposed | 5.60 | 9,912.00 | Form 4, filing 0000950170-24-075732 | |
| 2024-06-13 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 880 disposed | 28.38 | 24,974.40 | Form 4, filing 0001396814-24-000075 | |
| 2024-01-16 |
Nkarta, Inc. NKTX |
S, Open-market sale | 9,697 disposed | 8.74 | 84,751.78 | Form 4, filing 0000950170-24-005426 | |
| 2023-06-20 |
Nkarta, Inc. NKTX |
S, Open-market sale | 1,704 disposed | 4.85 | 8,264.40 | Form 4, filing 0001209191-23-039051 | |
| 2023-06-05 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 580 disposed | 38.34 | 22,236.62 | Form 4, filing 0001209191-23-035257 | |
| 2023-05-15 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 7,000 disposed | 41.85 | 292,950.00 | Form 4, filing 0001209191-23-030141 | |
| 2023-01-17 |
Nkarta, Inc. NKTX |
S, Open-market sale | 3,691 disposed | 5.49 | 20,263.59 | Form 4, filing 0001209191-23-003853 | |
| 2022-09-29 |
Nkarta, Inc. NKTX |
S, Open-market sale | 498 disposed | 13.00 | 6,474.00 | Form 4, filing 0000899243-22-032306 | |
| 2022-09-28 |
Nkarta, Inc. NKTX |
S, Open-market sale | 23,376 disposed | 13.03 | 304,614.99 | Form 4, filing 0000899243-22-032306 | |
| 2022-09-21 |
Nkarta, Inc. NKTX |
S, Open-market sale | 6,126 disposed | 13.01 | 79,717.03 | Form 4, filing 0000899243-22-031711 | |
| 2022-07-11 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 533 disposed | 56.95 | 30,354.35 | Form 4, filing 0001209191-22-042037 | |
| 2021-09-29 |
Nkarta, Inc. NKTX |
S, Open-market sale | 8,277 disposed | 27.20 | 225,134.40 | Form 4, filing 0000899243-21-038637 | |
| 2021-09-29 |
Nkarta, Inc. NKTX |
S, Open-market sale | 223 disposed | 26.53 | 5,916.19 | Form 4, filing 0000899243-21-038637 | |
| 2021-06-21 |
Nkarta, Inc. NKTX |
S, Open-market sale | 4,693 disposed | 26.39 | 123,848.27 | Form 4, filing 0000899243-21-025505 | |
| 2021-06-21 |
Nkarta, Inc. NKTX |
S, Open-market sale | 3,807 disposed | 26.89 | 102,370.23 | Form 4, filing 0000899243-21-025505 | |
| 2021-06-04 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 630 disposed | 62.19 | 39,179.70 | Form 4, filing 0001209191-21-038878 | |
| 2021-03-30 |
Nkarta, Inc. NKTX |
S, Open-market sale | 11,461 disposed | 30.23 | 346,466.03 | Form 4, filing 0000899243-21-014312 | |
| 2021-03-30 |
Nkarta, Inc. NKTX |
S, Open-market sale | 3,130 disposed | 32.21 | 100,817.30 | Form 4, filing 0000899243-21-014312 | |
| 2021-03-30 |
Nkarta, Inc. NKTX |
S, Open-market sale | 2,409 disposed | 31.24 | 75,257.16 | Form 4, filing 0000899243-21-014312 | |
| 2021-03-05 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 3,000 disposed | 65.88 | 197,640.00 | Form 4, filing 0001209191-21-018946 | |
| 2020-06-04 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 2,025 disposed | 47.46 | 96,106.50 | Form 4, filing 0001209191-20-035170 | |
| 2019-06-04 |
Pacira BioSciences, Inc. PCRX |
S, Open-market sale | 782 disposed | 42.66 | 33,360.12 | Form 4, filing 0001209191-19-035086 | |
| 2018-06-04 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 771 disposed | 33.90 | 26,136.90 | Form 4, filing 0001209191-18-036181 | |
| 2017-10-10 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 1,346 disposed | 4.24 | 5,709.46 | Form 4, filing 0001140361-17-038567 | |
| 2017-10-10 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 52 disposed | 4.26 | 221.58 | Form 4, filing 0001140361-17-038567 | |
| 2017-08-22 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 1,044 disposed | 36.15 | 37,740.60 | Form 4, filing 0001209191-17-050231 | |
| 2017-04-04 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 6,425 disposed | 9.06 | 58,198.94 | Form 4, filing 0001140361-17-015045 | |
| 2017-04-04 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 48 disposed | 8.87 | 425.62 | Form 4, filing 0001140361-17-015045 | |
| 2017-01-06 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 21,369 disposed | 8.52 | 181,957.04 | Form 4, filing 0001140361-17-001260 | |
| 2017-01-05 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 21,369 disposed | 8.17 | 174,601.83 | Form 4, filing 0001140361-17-001260 | |
| 2016-06-07 |
Relypsa Inc RLYP |
S, Open-market sale | 1,013 disposed | 19.32 | 19,572.98 | Form 4, filing 0001140361-16-069148 | |
| 2016-06-06 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 1,136 disposed | 46.95 | 53,335.20 | Form 4, filing 0001209191-16-126649 | |
| 2016-02-17 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 3,000 disposed | 60.00 | 180,000.00 | Form 4, filing 0001209191-16-101142 | |
| 2016-01-06 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 2,335 disposed | 22.30 | 52,071.90 | Form 4, filing 0001140361-16-047336 | |
| 2016-01-06 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 77 disposed | 21.54 | 1,658.77 | Form 4, filing 0001140361-16-047336 | |
| 2015-11-20 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 3,000 disposed | 60.00 | 180,000.00 | Form 4, filing 0001209191-15-082084 | |
| 2015-08-17 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 3,000 disposed | 60.02 | 180,060.00 | Form 4, filing 0001209191-15-067013 | |
| 2015-06-11 |
Relypsa Inc RLYP |
S, Open-market sale | 1,454 disposed | 34.63 | 50,359.14 | Form 4, filing 0001140361-15-024344 | |
| 2015-04-10 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 2,500 disposed | 88.00 | 220,000.00 | Form 4, filing 0001181431-15-005801 | |
| 2015-01-12 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 2,500 disposed | 94.06 | 235,150.00 | Form 4, filing 0001181431-15-000939 | |
| 2014-10-29 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 8,385 disposed | 21.90 | 183,618.08 | Form 4, filing 0001140361-14-039584 | |
| 2014-10-28 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 8,384 disposed | 22.08 | 185,123.75 | Form 4, filing 0001140361-14-039584 | |
| 2014-10-10 |
Pacira Pharmaceuticals, Inc. PCRX |
S, Open-market sale | 2,500 disposed | 94.87 | 237,175.00 | Form 4, filing 0001181431-14-034260 | |
| 2014-07-29 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 8,385 disposed | 22.28 | 186,801.87 | Form 4, filing 0001140361-14-030004 | |
| 2014-07-28 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 8,285 disposed | 21.93 | 181,666.02 | Form 4, filing 0001140361-14-030004 | |
| 2014-07-28 |
OncoMed Pharmaceuticals Inc OMED |
S, Open-market sale | 100 disposed | 22.70 | 2,270.00 | Form 4, filing 0001140361-14-030004 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 2
- Open-market sale 54
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. HASTINGS PAUL J, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001309702
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6